CN114259530A - Application of traditional Chinese medicine preparation in intervention of acute ischemic stroke - Google Patents

Abstract

The invention discloses an application of a traditional Chinese medicine preparation in intervention of acute ischemic stroke, belonging to the field of traditional Chinese medicines. According to the invention, an acute ischemic stroke animal model is established through middle cerebral artery embolism, and the protective effect of the gelatin and gelatin pill of the three-black-bone to nerves and the reduction of brain injury are verified through Longa's neurobehavioral scores and serum biochemical indexes (adjustment of superoxide dismutase (SOD), reduction of serum Malondialdehyde (MDA) level, increase of acetylcholine (ACh) and inhibition of acetylcholinesterase (AChE)), so that the acute ischemic stroke can be treated.

Description

Application of traditional Chinese medicine preparation in intervention of acute ischemic stroke

Technical Field

The invention relates to the field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine preparation in intervention of acute ischemic stroke.

Background

Stroke (also called stroke) is a common cerebrovascular disease, the morbidity rate is 246.8/10 ten thousand, the mortality rate is 114.8/10 ten thousand, wherein ischemic stroke accounts for about 87%, cerebral hemorrhage accounts for about 10%, subarachnoid hemorrhage accounts for about 3%, and the society is heavily burdened. Acute ischemic stroke is also called acute cerebral infarction, is a focal cerebral function impairment disease caused by the interruption of blood supply of local brain tissues, and accounts for 69.6 percent of cerebral stroke in China.

In recent years, acute stroke has become the third leading cause of death worldwide, and is a leading cause of permanent disability of patients, causing huge social and economic burden. Although the standardized age incidence of patients with acute cerebral infarction is reduced along with the implementation of a plurality of preventive measures such as reducing blood fat, reducing blood sugar, improving blood pressure, advocating sports and the like, the clinical symptom improvement rate of the patients is still not half at present. Therefore, the current situation of clinical treatment forces researchers to further explore the treatment strategy of acute cerebral infarction so as to realize the transformation of clinical application and improve the current treatment dilemma.

The Sanwu capsule and the Sanwu capsule pill are exclusive Chinese patent medicine products of Yunnan Jinwu Heiyao pharmaceutical limited company. Has been used clinically for more than forty years, and is used for treating rheumatism and apoplexy sequelae, apoplexy sequelae also known as cerebral apoplexy sequelae and cerebrovascular disease sequelae, and mainly refers to various cerebral dysfunctions left after the survival of cerebral apoplexy patients passes through an acute stage and a recovery stage. Depending on the location of brain injury, symptoms vary, and are often manifested as hemiplegia, facial hemiparalysis, speech disturbance, ataxia, dizziness, choking cough, various sensory disturbances, hemianopsia, cognitive dysfunction, affective disorders, and seizures. The serious patient can show a coma and a vegetative state, and different treatment schemes are selected according to different etiologies.

Because the research of the Sanwu capsule and the Sanwu capsule pill has no scientific theory system, the method is embodied: (1) the theoretical innovation and development are insufficient; (2) unclear clinical core value; (3) the scientific basis of the product is weak; (4) the quality control system is not complete. This results in that it: (1) the clinical value is not excavated enough; (2) the market value is expanded and weak; (3) the scientific value is not enough. Therefore, modern scientific and technical means are necessary to be applied to carry out secondary development and quality improvement on the Sanwu capsule and the Sanwu capsule pill products, and complete and systematic research is carried out.

Disclosure of Invention

The invention provides application of a traditional Chinese medicine preparation in intervening acute ischemic stroke, and establishes a mouse model of acute ischemic stroke through middle cerebral artery embolism (MCAO), thereby verifying that the traditional Chinese medicine preparation can play a role in neuroprotection and brain injury through regulating superoxide dismutase (SOD), reducing serum Malondialdehyde (MDA) level, increasing acetylcholine (ACh) and inhibiting acetylcholinesterase (AChE).

The invention firstly provides the application of a Chinese medicinal preparation in preparing the medicament for preventing and/or treating acute cerebral arterial thrombosis;

the traditional Chinese medicine preparation is prepared from the following effective components in parts by mass: 900 parts of raw kusnezoff monkshood root, 600 parts of raw common monkshood mother root, 450 parts of tuber fleeceflower root, 150 parts of prepared common monkshood daughter root, 300 parts of raw giant typhonium rhizome, 30 parts of frankincense, 90 parts of rock sugar and 500 parts of fresh pig trotters.

In the application, the traditional Chinese medicine preparation is a product of Sanwu glue, Sanwu capsule pills or other formulations.

The invention also provides the application of the Chinese medicinal preparation in preparing medicaments with the following functions;

(1) increasing the content of superoxide dismutase in serum;

(2) reducing the content of malondialdehyde in serum;

(3) the content of acetylcholine in serum is increased;

(4) reducing the content of acetylcholinesterase in serum;

(5) reducing brain injury by reducing cerebral infarction rate and infarct size;

the traditional Chinese medicine preparation is prepared from the following effective components in parts by mass: 900 parts of raw kusnezoff monkshood root, 600 parts of raw common monkshood mother root, 450 parts of tuber fleeceflower root, 150 parts of prepared common monkshood daughter root, 300 parts of raw giant typhonium rhizome, 30 parts of frankincense, 90 parts of rock sugar and 500 parts of fresh pig trotters.

In the application, the traditional Chinese medicine preparation is a product of Sanwu glue, Sanwu capsule pills or other formulations.

The invention has the following beneficial effects:

(1) the invention carries out secondary development on the exclusive products of the Sanwu gum and the Sanwu capsule of the Yunnan Jinwu Heiyao pharmaceutical company Limited, and firstly reveals the action mechanism of the Sanwu gum and the Sanwu capsule on the acute ischemic stroke;

(2) according to the invention, an acute ischemic stroke animal model is established through middle cerebral artery embolism, and the protective effect of the Sanwu glue and the Sanwu capsule on nerves is verified through Longa's neurobehavioral scores and serum biochemical indexes (acetylcholine (ACh), acetylcholinesterase (AChE), superoxide dismutase (SOD) and Malondialdehyde (MDA)), so that the acute ischemic stroke can be treated by the method;

(3) compared with the prior art, experiments show that the Sanwu glue and the Sanwu glue pills can reduce the cerebral infarction area and the infarction rate in the acute stage of acute ischemic stroke, are used for treating acute ischemic stroke diseases and not only for treating sequelae caused by the stroke.

Drawings

Figure 1 is the behavioural score.

FIG. 2 is a graph showing the level of SOD (U/mL) in serum; p <0.05, P <0.01, P <0.001, P < 0.0001.

FIG. 3 is MDA (nmol/mL) levels in serum; p <0.05, P <0.01, P <0.001, P < 0.0001.

FIG. 4 is a graph of serum levels of Ach (ug/mL), AChE (U/mL); p <0.05, P <0.01, P <0.001, P < 0.0001.

Figure 5 is TTC staining results.

Fig. 6 is a statistical chart of cerebral infarction area.

Detailed Description

The present invention is described in further detail below with reference to specific embodiments, which are given for the purpose of illustration only and are not intended to limit the scope of the invention.

The experimental procedures in the following examples are conventional unless otherwise specified.

Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.

The capsules of Sanwu used in the following examples were purchased from Yunan Jinwu Heiyao pharmaceutical Co., Ltd.

Gold was purchased from the pharmaceutical factory of wilmasu-pebo, germany.

Example 1

The animal is fed in an animal room of basic theory research institute of Chinese academy of science and science under the permission of the welfare committee of experimental animals, the room temperature is (24 +/-2 ℃) and the humidity is (50 +/-10)%, the illumination is normally replaced for 12 hours, and sterile feed and drinking water are supplied for 24 hours. Normal SD rats (280g ± 10g) acclimatized for 7 days were randomly divided into a blank group (Sham) (n ═ 8, equal doses of saline), a model group (model) (n ═ 12, equal doses of saline), a positive group (ginton) (gold multi n ═ 12, 20mg/kg), SWJW (triumulate capsule) -L (n ═ 12, 450mg/kg), SWJW-M (n ═ 12, 900mg/kg), SWJW-H (n ═ 12, 1800 mg/kg). Except for the blank group, each group was subjected to Middle Cerebral Artery Occlusion (MCAO) surgery to establish an acute ischemic stroke model. The normal saline, the positive medicine or the Sanwu capsule with equal dosage is orally taken immediately after operation, and the administration is continuously carried out for three days.

(1) Rats were behaviorally scored daily using Longa's method. The results are shown in FIG. 1. As can be seen from FIG. 1, the behavioral scores of the rats in the experimental animals in the model group were significantly higher than those in the blank group (P < 0.05). The behavioral scores of rats after the intervention of the Sanwu soft capsules and the positive drugs are obviously improved compared with a model group (P < 0.05).

(2) After the last dose, rats were fasted for 24h and the relevant procedures for drawing material were performed the following day. Wubab ratioAfter the rats are anesthetized with sodium, the abdominal aorta is subjected to blood sampling and anticoagulation at 3500 r.min^-1Centrifuging for 15 min at rotating speed, separating serum, and storing in a low-temperature refrigerator at-80 deg.C. The serum adopts Elisa method to detect superoxide dismutase (SOD) level in the serum, and is placed in a THERMO full-automatic enzyme standard instrument MK3 for detection, and the result is shown in figure 2. Serum is subjected to detection of Malondialdehyde (MDA) level by an Elisa method and is placed in a THERMO full-automatic enzyme marking instrument MK3 for detection, and the result is shown in figure 3. The serum is detected by adopting an Elisa method to detect acetylcholine (ACh) and acetylcholinesterase (AChE) in the serum, and is placed in a THERMO full-automatic enzyme marking instrument MK3 for detection, and the result is shown in figure 4.

From figure 2, it can be seen that the SOD values in the model group were significantly reduced compared to the blank group with a small amplitude of back-rise after positive drug intervention. The three-black capsule has obvious rising after dry prognosis. SOD (superoxide dismutase) plays a key role in free radical removal, brain tissues contain a large amount of unsaturated fatty acid, when body lipid is oxidized, a large amount of free radicals are accumulated, the consumption of SOD is obviously increased, and finally brain tissue damage is aggravated. This indicates that the Sanwu capsule can alleviate brain injury by supplementing SOD.

It can be seen from fig. 3 that the MDA values for the model group were significantly elevated compared to the blank group with a small amplitude of call back after positive drug intervention. The three-black capsule has obvious reduction after the dry prediction. MDA (malondialdehyde) is a protein that indicates the degree of membrane peroxidation, and the level of MDA in serum is indicative of the severity of post-infarction oxidative stress. The three-black capsule can reduce the brain injury by reducing the serum MDA level.

From fig. 4, it can be seen that the ACh values for the model group were significantly reduced compared to the blank group with a small amplitude of call back after positive drug intervention. The three-black capsule has obvious increase after the dry prediction. AChE values in the model group were significantly elevated compared to the blank group with a small amplitude of callback after positive drug intervention. The three-black capsule has obvious reduction after the dry prediction. Decrease in acetylcholine (ACh) and increase in acetylcholinesterase (AChE) are one of the mechanisms of neural hypofunction, and cholinesterase inhibitors are also effective drugs for improving cognitive function, and act to inhibit AChE in the synaptic cleft, thereby decreasing the breakdown of acetylcholine and increasing the concentration of acetylcholine in the synaptic cleft. The three-black capsule can play a role in neuroprotection and reduce brain injury by increasing acetylcholine (ACh) and inhibiting acetylcholinesterase (AChE).

(3) The rats were then sacrificed immediately, brain tissue was taken, the brains were fixed in 4% (volume percent) paraformaldehyde, TTC staining was performed (see fig. 5), and the relative infarct size was calculated (see fig. 6).

As can be seen from fig. 5, the infarct size was reduced in the positive drug group and the sanwu capsule administration group compared to the model group. As can be seen from fig. 6, the infarction rates of the groups administered with the three-black capsule were significantly improved compared to the model group.

Claims (4)

1. Application of a Chinese medicinal preparation in preparing medicine for preventing and/or treating acute cerebral arterial thrombosis;

the traditional Chinese medicine preparation is prepared from the following effective components in parts by mass: 900 parts of raw kusnezoff monkshood root, 600 parts of raw common monkshood mother root, 450 parts of tuber fleeceflower root, 150 parts of prepared common monkshood daughter root, 300 parts of raw giant typhonium rhizome, 30 parts of frankincense, 90 parts of rock sugar and 500 parts of fresh pig trotters.

2. Use according to claim 1, characterized in that: the traditional Chinese medicine preparation is a product of Sanwu glue, Sanwu capsule pills or other formulations.

3. The application of a Chinese medicinal preparation in preparing medicines with the following functions;

(1) increasing the content of superoxide dismutase in serum;

(2) reducing the content of malondialdehyde in serum;

(3) the content of acetylcholine in serum is increased;

(4) reducing the content of acetylcholinesterase in serum;

(5) reducing the cerebral infarction area and cerebral infarction rate;

the traditional Chinese medicine preparation is prepared from the following effective components in parts by mass: 900 parts of raw kusnezoff monkshood root, 600 parts of raw common monkshood mother root, 450 parts of tuber fleeceflower root, 150 parts of prepared common monkshood daughter root, 300 parts of raw giant typhonium rhizome, 30 parts of frankincense, 90 parts of rock sugar and 500 parts of fresh pig trotters.

4. Use according to claim 3, characterized in that: the traditional Chinese medicine preparation is a product of Sanwu glue, Sanwu capsule pills or other formulations.

Images